Latest Azelastine Stories
- Top-Line Results Expected in February 2015 - MISSISSAUGA, ON, Dec. 18, 2014 /PRNewswire/ - Nuvo Research Inc.
SOMERSET, N.J., Sept. 2 /PRNewswire/ -- Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR).
ASTEPRO(TM) (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, N.J., Jan. 15 /PRNewswire/ -- This allergy season, a new medication is available to manage the symptoms of seasonal allergic rhinitis, a condition that impacts as many as 40 million people in the United States.
Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation.
Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray.
Meda has submitted the registration application to the FDA for azelastine nasal spray in the new formulation with extra strength. The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending.
Regulatory News: Meda AB (STO:MEDAA): The registration application for azelastine nasal spray in the new formulation with Extra Strength has been submitted to the US Food and Drug Administration (FDA), seeking approval to treat symptoms of Seasonal Allergic Rhinitis and Perennial Allergic Rhinitis.
Meda has announced that the FDA has approved its registration application for azelastine eye drops in unit dose. The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics.
Regulatory News: The U.S. Food and Drug Administration (FDA) has approved Meda's (STO:MEDAA) registration application for azelastine eye drops in unit dose (Optivar Unit Dose).
- A trick or prank.